- First human-derived antibody which is suitable for prophylaxis, post-exposure prophylaxis, and treatment of MERS
- Therapeutic compound under development by Humabs BioMed on a non-profit basis
Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that Proceedings of the National Academy of Sciences (PNAS) has published a paper describing the isolation and characterization of a potent antibody from memory B-cells of a patient recovering from an infection with coronavirus (CoV) and the resulting Middle East Respiratory Syndrome (MERS). The antibody, which was isolated from the infected individual two years ago, is active against all three clinically relevant MERS-CoV strains and against a site that is conserved in all MERS strains, including the strain responsible for the latest outbreak in South Korea. Humabs has developed a production cell line allowing – depending on regulatory clearance – the antibody either to be made available on the basis of a compassionate use program or to enter Phase I trials within a few months.